Literature DB >> 7646927

Patterns of occurrence of the leukaemias.

F D Groves1, M S Linet, S S Devesa.   

Abstract

Despite a proliferation of epidemiological studies during the past two decades, aetiologies of the leukaemias remain poorly understood, and characterisation of descriptive patterns has been limited. Recent publications of international mortality and incidence data, along with the expanding U.S. database, make a comprehensive assessment of leukaemia patterns particularly timely. Total leukaemia mortality has dramatically declined among children and increased among the elderly, while incidence has declined somewhat (for Caucasian and African-American females) or remained stable (for African-American males) during the past two decades in the United States. Population-based 5-year relative survival for total leukaemia has risen substantially among children since the mid-1970s, and improved slightly among other age groups in the U.S., where survival is consistently higher among Caucasians than African-Americans, but differs little by gender. In a detailed assessment by leukaemia subtype, some important differences in geographic, racial/ethnic, age and trend patterns are identified, suggesting that the subtypes may have different aetiologic factors. Proven and suspected risk factors cannot explain more than a small fraction of the observed geographic and temporal variation in incidence. Several noteworthy subtype-specific characteristics or trends warrant further investigation: for acute lymphoid leukaemia (ALL), increasing incidence, with higher rates in Spanish and Latino populations; for chronic lymphoid leukaemia (CLL), declining incidence, with dramatically low rates among Asians; for acute myeloid leukaemia (AML), increasing incidence among African-American males; and for chronic myeloid leukaemia (CML), declining rates among Caucasian but not among African-Americans.

Entities:  

Mesh:

Year:  1995        PMID: 7646927     DOI: 10.1016/0959-8049(95)00024-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Are incidence rates of adult leukemia in the United States significantly associated with birth cohort?

Authors:  Philip S Rosenberg; Katherine L Wilson; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-12       Impact factor: 4.254

2.  The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire.

Authors:  K G Koffi; D C Nanho; E N'dathz; P Kouehion; R Dissieka; A Attia; K Mozard; A Tolo; K Boidy; N Meité; R Ayemou; M Sekongo; N Tea; I Sanogo
Journal:  Adv Hematol       Date:  2010-08-25

3.  The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study.

Authors:  Caroline Edijana Omoti; Alexander Ikenna Nwannadi; Jude Chike Obieche; Adesuwa Noma Olu-Eddo
Journal:  Pan Afr Med J       Date:  2012-01-20

Review 4.  Ionizing radiation and chronic lymphocytic leukemia.

Authors:  David B Richardson; Steve Wing; Jane Schroeder; Inge Schmitz-Feuerhake; Wolfgang Hoffmann
Journal:  Environ Health Perspect       Date:  2005-01       Impact factor: 9.031

5.  Space-time clustering of childhood leukaemia in Greece: evidence supporting a viral aetiology.

Authors:  E Petridou; K Revinthi; F E Alexander; S Haidas; D Koliouskas; H Kosmidis; F Piperopoulou; F Tzortzatou; D Trichopoulos
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

6.  Outcome of Frontline Treatment with "Generic" Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study.

Authors:  B Entasoltan; M A Bekadja; H Touhami; N Mehalhal; Z Zouaoui; N Mesli; M Talbi; A Bachiri; M Michallet
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-10-25       Impact factor: 2.576

7.  Assessing the Relationship between Chronic Lymphoid Leukemia Mortality Rates and Human Development Index: A 26-Year Trend Analysis Using Location-Scale Mixed Effects Model.

Authors:  Parisa Rezanejad Asl; Farid Zayeri; Alireza Moghisi
Journal:  Iran J Public Health       Date:  2021-03       Impact factor: 1.429

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.